Telapristone

Drug Profile

Telapristone

Alternative Names: CBD4124; CDB-4124; Proellex; Proellex®-V; Progenta; Telapristone acetate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Child Health and Human Development
  • Developer Northwestern University Feinberg School of Medicine; Repros Therapeutics
  • Class Antineoplastics; Antiprogestogens; Norpregnadienes; Small molecules
  • Mechanism of Action Selective progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Endometriosis; Uterine leiomyoma
  • Suspended Anaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in USA (Vaginal, Suppository)
  • 17 Jul 2017 Repros Therapeutics completes a phase II trial in Endometriosis in USA and Argentina (NCT01728454)
  • 01 May 2017 Repros Therapeutics terminates an extension phase II trial for Uterine leiomyoma in USA due to business decision (NCT02811159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top